Oric Pharmaceuticals Stock Performance
| ORIC Stock | USD 7.03 0.48 6.39% |
The company holds a Beta of 0.0421, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oric Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oric Pharmaceuticals is expected to be smaller as well. At this point, Oric Pharmaceuticals has a negative expected return of -0.0977%. Please make sure to check Oric Pharmaceuticals' treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Oric Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Oric Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound forward indicators, Oric Pharmaceuticals is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 23.9 M |
Oric |
Oric Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 819.00 in Oric Pharmaceuticals on December 24, 2024 and sell it today you would lose (116.00) from holding Oric Pharmaceuticals or give up 14.16% of portfolio value over 90 days. Oric Pharmaceuticals is currently does not generate positive expected returns and assumes 5.6741% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Oric, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oric Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oric Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oric Pharmaceuticals, and traders can use it to determine the average amount a Oric Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0172
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ORIC |
Estimated Market Risk
| 5.67 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oric Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oric Pharmaceuticals by adding Oric Pharmaceuticals to a well-diversified portfolio.
Oric Pharmaceuticals Fundamentals Growth
Oric Stock prices reflect investors' perceptions of the future prospects and financial health of Oric Pharmaceuticals, and Oric Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oric Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 246.19 M | ||||
| Shares Outstanding | 71.03 M | ||||
| Price To Book | 2.05 X | ||||
| EBITDA | (142.9 M) | ||||
| Cash And Equivalents | 227.06 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.05 % | ||||
| Book Value Per Share | 3.42 X | ||||
| Cash Flow From Operations | (112.66 M) | ||||
| Earnings Per Share | (1.83) X | ||||
| Total Asset | 274.14 M | ||||
| Retained Earnings | (562.77 M) | ||||
About Oric Pharmaceuticals Performance
By analyzing Oric Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Oric Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oric Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oric Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Oric Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 83 people.Things to note about Oric Pharmaceuticals performance evaluation
Checking the ongoing alerts about Oric Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oric Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oric Pharmaceuticals generated a negative expected return over the last 90 days | |
| Oric Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (127.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oric Pharmaceuticals currently holds about 227.06 M in cash with (112.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Over 91.0% of the company shares are owned by institutional investors |
- Analyzing Oric Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oric Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Oric Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oric Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oric Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oric Pharmaceuticals' stock. These opinions can provide insight into Oric Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oric Stock analysis
When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |